Jump to Main Content
Intranasal delivery of nanoparticles encapsulating BPI3V proteins induces an early humoral immune response in mice
- Mansoor, Fawad, Earley, Bernadette, Cassidy, Joseph P., Markey, Bryan, Foster, Colin, Doherty, Simon, Welsh, Michael D.
- Research in veterinary science 2014 v.96 no.3 pp. 551-557
- animal models, antibodies, antigens, blood serum, cattle, encapsulation, enzyme-linked immunosorbent assay, humoral immunity, immunoglobulin G, intranasal administration, laboratory animals, mice, mucosal immunity, nanoparticles, pathogens, solubilization, vaccine adjuvants, vaccine development, vaccines, viruses
- Vaccine adjuvants are typically designed to stimulate both systemic and mucosal immune responses. Polymeric nanoparticles have been used as adjuvants in the development of vaccines against a number of viral pathogens and tested in laboratory animals. The objective of the study was to assess if synthetic bovine parainfluenza virus type-3 (BPI3V) peptide motifs and solubilised BPI3V proteins encapsulated in poly (dl-lactic-co-glycolide) (PLGA) nanoparticles (NPs) induce specific humoral immune responses in a mouse model following intranasal administration. BPI3V-specific and peptide specific IgG ELISAs were used to measure serum IgG levels to BPI3V. Intranasal delivery of PLGA nanoparticles encapsulating BPI3V proteins elicited an early, gradually increasing BPI3V-specific IgG response that persisted over the subsequent 6 weeks, suggesting slow, persistent release of antigen. PLGA-BPI3V particles administered intranasally induced a stronger IgG antibody response at an earlier time point compared with solubilised BPI3V antigen alone. Such an approach could be deployed in the development of new generation vaccines.